Want to see LYEL full AI Analyst Report?
Top Page
Lyell Immunopharma
(NASDAQ:LYEL)
Select Model
Select Model
Rating:46Neutral
Price Target:
$9.00
▼(-41.90% Downside)
Action:Reiterated
Date:10/13/26
The score is primarily held down by weak financial performance (large losses and heavy negative free cash flow) and bearish technicals (price below all key moving averages with negative MACD). A positive corporate update on LYL273 manufacturing progress and safety management provides some support, while valuation is difficult to assess meaningfully due to negative earnings and no dividend.
Positive Factors
Proprietary Cell-Therapy Platform
Lyell’s proprietary T-cell reprogramming and cell-engineering capabilities provide a technology foundation across both CAR-T and TIL programs. If these approaches improve T-cell function and persistence as intended, they could support differentiated therapies and create multiple avenues for future clinical development.
Negative Factors
Minimal Revenue and Large Losses
Lyell remains firmly in an investment phase, with negligible revenue relative to its substantial net loss. This indicates that the company has not yet established a commercial revenue base or operating leverage, leaving future value dependent on successful clinical development and eventual product commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Cell-Therapy Platform
Lyell’s proprietary T-cell reprogramming and cell-engineering capabilities provide a technology foundation across both CAR-T and TIL programs. If these approaches improve T-cell function and persistence as intended, they could support differentiated therapies and create multiple avenues for future clinical development.
Read all positive factors
Lyell Immunopharma (LYEL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$228.14M
Dividend YieldN/A
Average Volume (3M)168.39K
Price to Earnings (P/E)―
Beta (1Y)1.79
Revenue Growth-55.00%
EPS Growth51.58%
CountryUS
Employees161
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-16.01
Shares Outstanding24,505,140
10 Day Avg. Volume189,429
30 Day Avg. Volume168,394
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.12
Price to Sales (P/S)14614.51
P/FCF Ratio-3.49
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue6.32K
Enterprise Value/Gross Profit-74.08
Enterprise Value/Ebitda-0.71
Forecast
1Y Price Target
$36.20Price Target Upside133.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-7.24
Revenue Forecast (FY)$11.88K
Lyell Immunopharma Business Overview & Revenue Model
Company Description
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabt...
Lyell Immunopharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.00K | 36.00K | 61.00K | 130.00K | 84.68M | 10.65M |
| Gross Profit | -2.31M | -11.50M | 61.00K | 130.00K | 84.68M | 10.65M |
| EBITDA | -238.96M | -262.91M | -200.64M | -214.38M | -165.10M | -236.59M |
| Net Income | -248.48M | -274.45M | -342.99M | -234.63M | -183.12M | -250.22M |
Balance Sheet | ||||||
| Total Assets | 311.15M | 340.05M | 490.86M | 750.03M | 937.56M | 1.13B |
| Cash, Cash Equivalents and Short-Term Investments | 204.10M | 247.22M | 370.53M | 546.22M | 640.15M | 614.79M |
| Total Debt | 36.93M | 50.99M | 58.97M | 63.17M | 67.70M | 67.82M |
| Total Liabilities | 77.34M | 91.85M | 108.03M | 95.08M | 104.31M | 197.62M |
| Stockholders Equity | 233.81M | 248.20M | 382.82M | 654.95M | 833.25M | 929.79M |
Cash Flow | ||||||
| Free Cash Flow | -133.97M | -150.80M | -162.86M | -166.38M | -193.83M | -191.75M |
| Operating Cash Flow | -133.26M | -150.02M | -162.39M | -163.69M | -169.56M | -126.25M |
| Investing Cash Flow | 4.98M | 54.10M | 122.42M | 184.05M | -11.54M | -121.57M |
| Financing Cash Flow | 102.47M | 50.41M | 1.33M | 1.74M | 10.63M | 401.24M |
Lyell Immunopharma Technical Analysis
Neutral
15.49
Price Trends
11.37
Negative
12.40
Negative
17.13
Negative
Market Momentum
-0.50
Negative
45.99
Neutral
74.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYEL, the sentiment is Neutral. The current price of 15.49 is above the 20-day moving average (MA) of 8.89, above the 50-day MA of 11.37, and below the 200-day MA of 17.13, indicating a neutral trend. The MACD of -0.50 indicates Negative momentum. The RSI at 45.99 is Neutral, neither overbought nor oversold. The STOCH value of 74.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LYEL.
Lyell Immunopharma Risk Analysis
Lyell Immunopharma disclosed 66 risk factors in its most recent earnings report. Lyell Immunopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lyell Immunopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.17B | -3.96 | -159.32% | ― | ― | 2.95% | |
47 Neutral | $368.59M | -3.21 | -196.63% | ― | 20.83% | 73.89% | |
46 Neutral | $228.14M | -0.58 | -91.62% | ― | -55.00% | 51.58% | |
46 Neutral | $43.90M | -1.51 | -74.76% | ― | -100.00% | 44.94% | |
45 Neutral | $250.29M | -14.25 | -5.76% | ― | ― | 93.45% |
* Healthcare Sector Average
LYEL
Lyell Immunopharma
9.31
-7.92
-45.97%
RCKT
Rocket Pharmaceuticals
2.28
-1.66
-42.13%
EDIT
Editas Medicine
2.40
-0.85
-26.15%
MREO
Mereo Biopharma Group Plc
0.28
-1.73
-86.25%
REPL
Replimune Group
12.47
3.14
33.65%
Lyell Immunopharma Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Lyell Immunopharma advances LYL273 CAR T program
Positive
Sep 10, 2026
On September 10, 2026, Lyell Immunopharma announced it had completed the technology transfer for its next-generation GCC-targeted CAR T-cell candidate LYL273 to the LyFE Manufacturing Center in Bothell, Washington, following U.S. Food and Drug Adm...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.